mProX™ Human GALR3 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- GPCR Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human GALR3 Stable Cell Line (S01YF-0923-PY73). Click the button above to contact us or submit your feedback about this product.
Barbara (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Matthew (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The TCGA COAD database's normalized expression levels for GalR mRNA.
The columns describe GalR mRNA members, while the rows represent the patient IDs who are involved in colorectal cancer study. The expression of GalR mRNA in a neighboring normal portion of the colon (n = 7) is described in the bottom seven rows. The remaining rows (n = 129) show GalR mRNA expression in colorectal cancer.
Ref: Kiezun, Jacek, et al. "Galanin Receptors (GalR1, GalR2, and GalR3) Expression in Colorectal Cancer Tissue and Correlations to the Overall Survival and Poor Prognosis of CRC Patients." International Journal of Molecular Sciences 23.7 (2022): 3735.
Pubmed: 35409094
DOI: 10.3390/ijms23073735
Research Highlights
Akkoc S, et al. "Synthesis, characterization, antiproliferative activity, docking, and molecular ." Journal of biomolecular structure & dynamics, 2023.
Cancer is a major global public health issue affecting millions of individuals annually. The development of new anti-cancer drugs is essential to combat various forms of cancer and overcome drug resistance. Previous research has shown that benzimidazole derivatives have potential as anti-cancer agents. Therefore, six new 1,3-dihydro-2H-benzimidazol-2-one-based molecules (2a-f) were synthesized and their structures confirmed through spectroscopic methods. These molecules were then tested for their anticancer activity against a panel of human cancer cell lines, as well as a normal human lung cell line for selectivity. Results showed that compound 2d exhibited the strongest cytotoxic effects against DLD-1 and MDA-MB-231 cell lines compared to the other compounds. Molecular docking and dynamics simulation studies revealed the high binding potential of compound 2d with the GALR3 target. Further computational pharmacokinetic studies also demonstrated that the newly synthesized compounds possess optimal drug-like properties. This study was conducted by a team led by Ramaswamy H. Sarma.
Pubmed:
37787572
DOI:
10.1080/07391102.2023.2262601
Ortega JT, et al. "Galanin receptor 3 - A new pharmacological target in retina degeneration.." Pharmacological research, 2023.
The neuropeptide galanin receptor 3 (GALR3) is a class A G protein-coupled receptor (GPCR) that is widely expressed in the nervous system, including the retina. GALR3 plays a role in immune and inflammatory responses, which are crucial for maintaining retina health and vision. In this study, the researchers investigated the involvement of GALR3 in retina pathologies triggered by bright light and a mutation in the rhodopsin (RHO) gene. Using a combination of pharmacological inhibition and genetic depletion, they found that GALR3 signaling is involved in the cellular stress response to all-trans-retinal toxicity and plays a role in protecting against bright light-induced retina damage and retinitis pigmentosa. These results suggest that GALR3 may be a potential therapeutic target for treating retinal degeneration.
Pubmed:
36693600
DOI:
10.1016/j.phrs.2023.106675
